BioWorld Asia

May 8, 2002

GenOway Enters Drug Target Deal, Plans $5.4M Financing

PARIS - GenOway SA signed a nonexclusive agreement with the French pharmaceutical company Servier for the in vivo validation of a number of therapeutic gene targets. (BioWorld International Read More

EU Advisers Support Stem Cell Research, Cautious On Patents

Reprogramming Technique Raises Hopes Of Adult Skin Cell Therapy

Screentec Signals Discovery Ambitions With Name Change

Other News To Note

MMI Raises £1.6M In Placement To Finance Start-Ups, Incubators

Proteome Sciences’ Data Show Sensitivity, Specificity In Test

Personal Chemistry Purchases ESyTech To Extend Platform

Cerep Completes Drug Target Validation Under 1999 BMS Deal

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

New 5-HT2C receptor agonists reported in Hansoh patent

BioWorld Science

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...